IGHE and atrial fibrillation: When considering the antibody‐mediated response, multiple biomarkers are needed to assess the complex pathophysiology of ABPA, with type I (IgE‐mediated) and type III (IgG‐mediated) adaptive immune responses to AF in a context of type 2 inflammation.